Last edition
News about "Moitreyee Chatterjee-Kishore"
US FDA Approves PADCEV Plus Keytruda for Muscle-Invasive Bladder Cancer
The US Food and Drug Administration (FDA) has approved PADCEV plus Keytruda as the first and only platinum-free neoadjuvant and adjuvant treatment for adults with Muscle-Invasive Bladder Cancer (MIBC), regardless of cisplatin eligibility.
Moitreyee Chatterjee-Kishore | 13/07/2026 | By News Bureau
US FDA Approves PADCEV plus Keytruda for Certain Patients with Bladder Cancer
PADCEV plus Keytruda is the first and only approved perioperative treatment regimen that can improve survival over current standard of care (surgery alone) in cisplatin-ineligible patients with Muscle-Invasive Bladder Cancer (MIBC).
Moitreyee Chatterjee-Kishore | 24/11/2025 | By Dineshwori | 170
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy